Table 2.

Net Monetary/Health Benefit

	Nivolumab + Ipilimumab vs. Pembrolizumab + Axitinib	Pembrolizumab + Axitinib vs. Avelumab + Axitinib	Nivolumab + Ipilimumab vs. Avelumab + Axitinib
Incremental cost	($13,041.03)	($92,285.19)	($105,326.22)
Incremental benefit	0.27	0.82	1.09
Incremental cost-effectiveness ratio	($47,504.73)	($113,015.87)	($96,533.11)
Net monetary benefit	$54,219.14	$214,770.44	$268,989.58
Net health benefit	0.36	1.43	1.79

bilistic sensitivity analysis was conducted using 10,000 Monte Carlo simulations fluctuating the model parameters over realistic probability distributions.